Distinction between therapy and enhancement in germline edits

Introduction

The distinction between therapy and enhancement in germline editing is an important legal, ethical, and scientific issue in modern biotechnology. Germline editing refers to genetic modifications made to reproductive cells, embryos, or their precursors in ways that may be inherited by future generations. Technologies such as CRISPR-Cas9 have created possibilities for modifying genetic material to address inherited diseases and potentially influence human characteristics.

The central legal question is whether genetic modification should be permitted only to prevent or treat serious genetic disorders or whether it may also be used to improve characteristics such as physical abilities, intelligence, appearance, or other inherited traits.

Therapeutic germline editing aims to prevent or correct disease-causing genetic conditions. Enhancement germline editing, by contrast, seeks to introduce genetic changes intended to improve characteristics beyond the prevention or treatment of disease. Although the distinction appears straightforward, it becomes complicated when a genetic characteristic has both medical and non-medical implications.

This distinction is important because therapeutic interventions may be justified by medical necessity, while enhancement interventions raise concerns about inequality, discrimination, human dignity, informed consent, and the long-term consequences of hereditary genetic modifications.

Meaning of therapeutic germline editing

Therapeutic germline editing refers to genetic modification intended to prevent or correct inherited disorders that may cause serious illness or disability in future generations.

Its principal objective is disease prevention rather than the improvement of ordinary human characteristics.

Examples of intended therapeutic objectives include:

Preventing the transmission of serious inherited genetic disorders.

Correcting disease-associated genetic variations.

Reducing the risk of certain hereditary conditions.

Preventing the transmission of specific genetic abnormalities.

Supporting future medical research into inherited diseases.

However, therapeutic intention alone does not establish legal permission. Germline interventions raise additional questions concerning safety, scientific validity, consent, and intergenerational consequences.

Meaning of enhancement germline editing

Enhancement germline editing refers to genetic modification intended to improve inherited human characteristics beyond the prevention or treatment of recognised diseases.

Its objectives may include altering characteristics associated with physical performance, appearance, cognitive abilities, or other biological attributes.

Examples of proposed enhancement objectives include:

Modifying genetic characteristics associated with physical performance.

Attempting to influence inherited cognitive characteristics.

Altering biological characteristics associated with appearance.

Attempting to increase resistance to certain environmental conditions.

Introducing genetic modifications for non-medical preferences.

Enhancement interventions are especially controversial because many human characteristics are influenced by numerous genes, environmental conditions, education, and social factors. Therefore, claims that a particular genetic modification can reliably produce a complex enhancement are scientifically uncertain.

Major differences between therapy and enhancement

Legal framework governing germline editing in India

1. Constitution of India

The Constitution provides important principles for evaluating germline editing.

Article 14: Guarantees equality before the law and equal protection of laws.

Article 21: Protects life, personal liberty, dignity, and privacy.

Article 19: Protects specified freedoms, subject to constitutional restrictions.

Therapeutic genetic interventions may raise questions concerning reproductive autonomy and the protection of future generations. Enhancement interventions may raise additional concerns about inequality and discriminatory treatment.

However, constitutional rights do not create an unrestricted right to conduct heritable genetic modification.

2. ICMR National Guidelines for Stem Cell Research, 2017

The Indian Council of Medical Research and Department of Biotechnology issued the National Guidelines for Stem Cell Research, 2017.

These guidelines establish ethical and regulatory standards for stem cell research.

They distinguish permissible research activities from prohibited or restricted activities and provide safeguards concerning human embryos, reproductive applications, and research oversight.

The guidelines are relevant to germline editing involving human embryos and stem-cell-related research.

3. Department of Biotechnology guidelines

India's regulatory framework for recombinant DNA research and related biotechnology activities includes guidelines issued by the Department of Biotechnology.

The Rules for the Manufacture, Use, Import, Export and Storage of Hazardous Microorganisms, Genetically Engineered Organisms or Cells, 1989, issued under the Environment (Protection) Act, 1986, provide an important regulatory foundation for specified genetically engineered organisms and related activities.

These requirements must be considered alongside applicable biomedical research and reproductive regulations.

4. Assisted Reproductive Technology (Regulation) Act, 2021

The Assisted Reproductive Technology (Regulation) Act, 2021, regulates assisted reproductive technology clinics and banks in India.

Its framework addresses ethical and legal requirements concerning reproductive services, donor information, and the protection of individuals undergoing assisted reproduction.

Germline editing in reproductive settings must be considered within the applicable restrictions and regulatory requirements rather than treated as an ordinary reproductive service.

5. International ethical standards

International instruments provide additional guidance on the distinction between therapeutic and enhancement applications.

The UNESCO Universal Declaration on the Human Genome and Human Rights, 1997, emphasises human dignity and protection against genetic discrimination.

Article 24 of the Convention on Human Rights and Biomedicine (Oviedo Convention), 1997, addresses compensation for undue damage resulting from medical interventions.

The World Health Organization's 2021 recommendations on human genome editing emphasise governance, safety, transparency, and international cooperation.

Ethical and legal challenges

1. Intergenerational consent

Germline modifications may affect individuals who have not yet been born. Future generations cannot provide consent to genetic changes that may influence their inherited biological characteristics.

This creates a fundamental ethical difference between ordinary medical treatment and heritable genetic interventions.

2. Human dignity and autonomy

Therapeutic editing may be presented as a means of preventing serious disease. Enhancement editing raises concerns about treating human characteristics as products that can be selected according to parental preferences.

The legal challenge is to protect reproductive autonomy without permitting practices that undermine human dignity or equality.

3. Genetic discrimination

Enhancement technologies may create unequal access to genetic advantages. Wealthier individuals could potentially obtain access to expensive interventions, increasing existing social inequalities.

4. Scientific uncertainty

The human genome contains complex interactions between genetic variations and environmental influences. Modifying one genetic characteristic may produce unintended consequences affecting other biological functions.

5. Protection of future generations

A genetic modification introduced into reproductive cells may be inherited by descendants. Therefore, legal responsibility extends beyond immediate patients and raises questions concerning long-term monitoring and accountability.

Relevant case laws and legal precedents

There is currently no established Indian Supreme Court judgment directly deciding the distinction between therapeutic and enhancement germline editing. Nevertheless, constitutional and international decisions provide important principles.

1. Justice K.S. Puttaswamy v. Union of India (2017)

The Supreme Court recognised privacy as a fundamental right under Article 21 and other constitutional freedoms.

Legal significance: Genetic information is closely connected with personal identity, autonomy, and privacy. Germline editing policies must respect individual dignity and protect genetic information against unauthorised use. The judgment is relevant to both therapeutic and enhancement interventions.

2. Suchita Srivastava v. Chandigarh Administration (2009)

The Supreme Court recognised reproductive choice as an important dimension of personal liberty under Article 21.

Legal significance: The judgment establishes that reproductive autonomy deserves constitutional protection. However, reproductive autonomy does not automatically establish a right to undertake every form of germline modification, particularly where future generations may be affected.

3. Common Cause v. Union of India (2018)

The Supreme Court examined individual autonomy, dignity, and medical decision-making in the context of end-of-life care.

Legal significance: The decision reinforces the importance of respecting personal autonomy and dignity in medical interventions. These principles are relevant when evaluating consent and ethical responsibility in advanced genetic technologies.

4. National Legal Services Authority v. Union of India (2014)

The Supreme Court recognised the rights and dignity of transgender persons and emphasised constitutional equality and individual identity.

Legal significance: The judgment provides an important foundation for opposing discrimination based on biological characteristics and socially constructed expectations. It is relevant to concerns that enhancement technologies could reinforce discriminatory standards of human identity.

5. Costa and Pavan v. Italy (2012)

The European Court of Human Rights examined restrictions on access to preimplantation genetic diagnosis for a couple at risk of transmitting a serious inherited disease.

Legal significance: The Court examined reproductive autonomy and the proportionality of restrictions on access to reproductive genetic services. The case is relevant to the therapeutic use of genetic technologies, although it did not concern permission for heritable genome editing.

6. A.P., Garçon and Nicot v. France (2017)

The European Court of Human Rights examined legal requirements affecting recognition of gender identity and the relationship between personal autonomy and bodily integrity.

Legal significance: The decision provides broader principles concerning bodily autonomy and personal identity. These principles may inform ethical discussions about genetic interventions, although the case did not directly concern germline editing.

International regulatory approaches

Different countries and international organisations have adopted varying approaches to germline editing.

1. World Health Organization

The WHO's 2021 recommendations on human genome editing emphasise international governance, safety, transparency, and oversight of both somatic and heritable genome editing.

2. UNESCO

The UNESCO Universal Declaration on the Human Genome and Human Rights, 1997, establishes human dignity as a central principle in genetic research and applications.

3. Council of Europe

The Oviedo Convention, 1997, provides that interventions seeking to modify the human genome must not aim to introduce modifications in the genome of descendants under Article 13.

4. International scientific governance

International scientific organisations have emphasised that heritable genome editing requires extensive safety evaluation, public engagement, and appropriate regulatory oversight before any clinical application could be considered.

Measures for establishing a clear legal distinction

A comprehensive legal framework should distinguish therapeutic applications from enhancement applications through objective regulatory criteria.

Important measures include:

Defining serious disease prevention and non-medical enhancement separately.

Establishing independent scientific and ethical review committees.

Requiring strong evidence of safety and clinical necessity.

Protecting reproductive autonomy and informed consent.

Preventing genetic discrimination in employment and insurance.

Establishing strict oversight of embryo-related research.

Protecting future generations from avoidable genetic risks.

Promoting international cooperation and transparent research reporting.

Regulatory authorities should also avoid assuming that every genetic characteristic associated with disability requires correction. The rights and dignity of persons with disabilities must remain central to genetic policy.

Conclusion

The distinction between therapy and enhancement in germline editing is fundamental to the legal governance of modern biotechnology. Therapeutic germline editing aims to prevent or correct serious inherited diseases, whereas enhancement germline editing seeks to modify human characteristics beyond conventional medical purposes.

Although therapeutic applications may offer potential medical benefits, both categories raise significant questions concerning safety, reproductive autonomy, human dignity, and intergenerational responsibility. In India, constitutional protections, ICMR guidelines, the Assisted Reproductive Technology (Regulation) Act, 2021, and biotechnology regulations provide relevant legal foundations.

Judicial decisions such as Justice K.S. Puttaswamy v. Union of India, Suchita Srivastava v. Chandigarh Administration, and Common Cause v. Union of India reinforce the importance of privacy, autonomy, and dignity. Ultimately, germline editing governance must distinguish legitimate medical objectives from non-therapeutic enhancement while protecting equality, scientific integrity, and the interests of future generations.